FDA turns to Fresenius imports from EU to help with common cancer drug shortage
The FDA acknowledged today that it’s been allowing temporary imports of the commonly used cancer drug cisplatin from Fresenius Kabi to help shore up the continuing shortage of the drug nationwide.
The product that’s being allowed into the country is marketed in Europe and manufactured in India, but still not FDA-approved, according to a letter FDA sent Aug. 30 and shared on social media Thursday. FDA’s drug shortage site said there would be “limited availability” of the product beginning Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.